The Global Medtech Industry: Rewiring Medtech in a Post-Pandemic World
The medtech industry is undergoing rapid change to address evolving global market dynamics. This has been further accelerated by the pandemic. This white paper from IQVIA – an associate member of AdvaMed® – discusses how global markets and specific therapeutic areas are poised for growth over the next decade. Read this white paper to help inform business strategy.
Related Reading
News / Global & Trade / Government & Legislative Affairs / Health Access / Supply Chain / Tariffs
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
September 25, 2025
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/12
September 12, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/5
September 5, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/22
August 22, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/15
August 19, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
August 12, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/25
July 25, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/18
July 18, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.